Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378612 | 0.94 | TGFBR1 (0.52) | TGFBR1PDPK1IKBKECYP3A4CYP1A2 | |
| SCHEMBL3385991 | 0.85 | TGFBR1 (0.41) | TGFBR1PDPK1IKBKECYP3A4CYP1A2 | |
| SCHEMBL14877111 | 0.82 | IKBKE (0.49) | TGFBR1PDPK1IKBKECYP1A2DYRK1A | |
| SCHEMBL12440185 | 0.78 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP1A2 | |
| SCHEMBL3379333 | 0.77 | IDO1 (0.39) | TGFBR1CYP3A4CYP1A2 | |
| SCHEMBL3390023 | 0.77 | TGFBR1 (0.40) | TGFBR1CYP3A4CYP1A2 | |
| SCHEMBL3390252 | 0.77 | TGFBR1 (0.40) | TGFBR1CYP3A4CYP1A2RET | |
| SCHEMBL244421 | 0.77 | KDR (0.47) | TGFBR1IKBKECYP3A4CYP1A2 | |
| SCHEMBL3382050 | 0.76 | IDO1 (0.40) | TGFBR1PDPK1IKBKEGSK3BCDK2 | |
| Formic Acid SCHEMBL248316 | 0.75 | GSK3B (0.46) | TGFBR1CYP3A4CYP1A2DYRK1ANFATC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2585461-A1 | 2,4- DIARYL - SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | Merck Patent GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| CN-102958930-A | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH | 2013-03-06 | — | — | CN | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | TGFBR1 1/4885PDPK1 42/4885IKBKE 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.